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ARTICLE
αv integrins on mesenchymal cells regulate skeletal
and cardiac muscle ﬁbrosis
I.R. Murray1,2, Z.N. Gonzalez2, J. Baily2, R. Dobie3, R.J. Wallace1, A.C. Mackinnon3, J.R. Smith3, S.N. Greenhalgh3,
A.I. Thompson3, K.P. Conroy3, D.W. Griggs4, P.G. Ruminski4, G.A. Gray5, M. Singh4, M.A. Campbell4,
T.J. Kendall 3, J. Dai6,7, Y. Li6,7, J.P. Iredale8, H. Simpson1, J. Huard9,10, B. Péault2,11 & N.C. Henderson3
Mesenchymal cells expressing platelet-derived growth factor receptor beta (PDGFRβ) are
known to be important in ﬁbrosis of organs such as the liver and kidney. Here we show that
PDGFRβ+ cells contribute to skeletal muscle and cardiac ﬁbrosis via a mechanism that
depends on αv integrins. Mice in which αv integrin is depleted in PDGFRβ+ cells are protected
from cardiotoxin and laceration-induced skeletal muscle ﬁbrosis and angiotensin II-induced
cardiac ﬁbrosis. In addition, a small-molecule inhibitor of αv integrins attenuates ﬁbrosis, even
when pre-established, in both skeletal and cardiac muscle, and improves skeletal muscle
function. αv integrin blockade also reduces TGFβ activation in primary human skeletal muscle
and cardiac PDGFRβ+ cells, suggesting that αv integrin inhibitors may be effective for the
treatment and prevention of a broad range of muscle ﬁbroses.
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Skeletal and cardiac muscle ﬁbrosis are both characterised bythe excessive production and deposition of collagenousextracellular matrix by myoﬁbroblasts, compromising
myoﬁbre contractility, tissue architecture and ultimately organ
function1–3. Fibrosis secondary to skeletal muscle injury results in
signiﬁcant functional impairment and predisposes to further
injury4, 5. Cardiac ﬁbrosis is associated with considerable mor-
bidity and mortality, and is a leading cause of death in indus-
trialised countries6. However, the cellular and molecular
mechanisms regulating ﬁbrosis in these tissues remain poorly
understood and treatment options are severely limited6.
Iterative injury in any organ triggers a complex cascade of
cellular and molecular events, including activation of extracellular
matrix-producing myoﬁbroblasts1–3. While this appropriate
wound-healing response may be beneﬁcial in the short term,
persistence of myoﬁbroblasts results in scar tissue formation that
ultimately impairs tissue function. Within skeletal muscle, ﬁbro-
adipogenic progenitors expressing platelet-derived growth factor
receptor alpha (PDGFRα) have been identiﬁed as key con-
tributors to the myoﬁbroblast pool in response to injury7, 8.
Although the mesenchymal marker platelet-derived growth factor
receptor beta (PDGFRβ) is increasingly recognised as labelling
pro-ﬁbrotic cells within multiple organs including liver, lung and
kidney9–11, much less is known about the PDGFRβ+ cellular
compartment within skeletal and cardiac muscle. In keeping with
the emerging view that ﬁbrosis in different organs and disease
states may share common cellular and molecular mechanisms, we
hypothesised that PDGFRβ+ cells are also key regulators of the
ﬁbrogenic process in skeletal and cardiac muscle.
Transforming growth factor beta (TGFβ) is a key pro-
ﬁbrogenic cytokine in multiple organs including skeletal muscle
and heart12–14. Its critical role in multiple biological processes,
not least immunity and carcinogenesis, precludes pan-TGFβ
blockade as a feasible therapy15. Therefore, the molecular path-
ways regulating local activation of TGFβ at the site of injury and
ﬁbrogenesis represent attractive targets for novel anti-ﬁbrotic
therapies. αv integrins have been demonstrated to play a key role
in the activation of latent TGFβ1 and TGFβ316. Speciﬁcally, all
ﬁve αv integrins interact with a linear arginine-glycine-aspartic
acid (RGD) motif present in the latency-associated peptide, which
maintains TGFβ in an inactive state in the extracellular matrix.
Active TGFβ can be released from the latency-associated peptide
following αv integrin binding17–20. Furthermore, αv integrins,
including integrins αvβ1, αvβ6 and αvβ8, have been shown to be
key regulators of ﬁbrogenesis in vivo in pre-clinical models of
lung, liver and kidney ﬁbrosis9, 17, 21, 22. However, the role of αv
integrins in the regulation of muscle ﬁbrosis has not previously
been explored.
We exploited a recently developed genetic system (Pdgfrb-Cre)
in mice to identify molecular mechanisms driving skeletal and
cardiac muscle ﬁbrosis, and focussed on the integrin αv subunit
because of the aforementioned role of αv integrins in activating
latent TGFβ, a central mediator of ﬁbrosis. In addition to a
genetic approach, we investigated the utility of a small molecule
inhibitor of αv integrins (CWHM 12) as a potential anti-ﬁbrotic
therapy for both skeletal and cardiac muscle ﬁbrosis. We estab-
lished that selective depletion of αv integrins on PDGFRβ+ cells
protects mice from ﬁbrosis in both these muscle types, and αv
integrin depletion on PDGFRβ+ cells had no adverse effects on
skeletal muscle regeneration. Furthermore, treatment with
CWHM 12 attenuates ﬁbrosis in both skeletal muscle and heart,
even after the ﬁbrotic process is established.
Results
Pdgfrb-Cre targets recombination in skeletal muscle PDGFRβ+
cells. In uninjured skeletal muscle, we found that Pdgfrb-Cre
induced highly efﬁcient recombination in PDGFRβ+ cells. This
was demonstrated using double ﬂuorescent mTmG reporter mice,
which express membrane-targeted tandem dimer Tomato
(tdTomato) before Cre-mediated excision and membrane-
targeted green ﬂuorescent protein (GFP) after excision23
(Fig. 1a). Colocalisation studies of PDGFRβ-stained muscle sec-
tions from mTmG;Pdgfrb-Cre mice demonstrated faithful
reporting, with 97.5% (SEM 0.46) of cells staining for PDGFRβ
antibody reporting GFP, and 95.3% (SEM 1.08) of GFP+ cells
staining positively for PDGFRβ (Fig. 1b, c). Virtually all GFP+
cells sorted from mTmG;Pdgfrb-Cre mouse muscle stained
positively with anti-PDGFRβ antibody on ﬂow cytometric ana-
lysis (Fig. 1d). To further assess speciﬁcity of Pdgfrb-Cre-
mediated recombination, we stained uninjured skeletal muscle
from mTmG;Pdgfrb-Cre mice with antibodies to CD31, ICAM-2
and CD144 (endothelial cells), CD45 (haematopoietic cells) and
fast myosin (myoﬁbres) (Supplementary Fig. 1). As expected,
PDGFRβ was consistently expressed in close proximity to CD31+
endothelial cells and was not expressed by haematopoietic cells or
myoﬁbres, further conﬁrming the speciﬁcity of Pdgfrb-Cre to
mark PDGFRβ+ cells in skeletal muscle.
To evaluate the contribution of PDGFRβ+ cells to the
myoﬁbroblast pool following injury, we observed the distribution
of GFP+ cells in skeletal muscle of mTmG;Pdgfrb-Cre mice
following injury induced by intramuscular injection of cardio-
toxin (CTX) (Fig. 1e). The ﬁeld coverage of GFP+ cells and the
number of GFP+ nuclei in skeletal muscle was signiﬁcantly higher
in mice receiving CTX injections compared to control mice
receiving PBS injections, with signiﬁcant differences maintained
to at least 60 days post injection (Fig. 1f, g). To further
characterise PDGFRβ+ cells in the skeletal muscle of mTmG;
Pdgfrb-Cre mice, we isolated PDGFRβ+ reporter cells from
control and injured mice. Quantitative PCR (qPCR) of mRNA
obtained from viable GFP+ cells showed dramatic induction of
multiple genes associated with the transition of quiescent
PDGFRβ+ cells to the activated myoﬁbroblast phenotype
following CTX-induced muscle injury (Fig. 1h). These included
the genes encoding PDGFRβ, alpha-smooth muscle actin
(αSMA), TGFβ1, tissue inhibitor of metalloproteinase 1 (TIMP1),
matrix metallopeptidase 2 (MMP2), matrix metallopeptidase 13
(MMP13), collagen 1 (Col1a1) and collagen 3 (Col3a1).
Furthermore, to assess whether PDGFRβ+ cells isolated from
skeletal muscle behave in a similar way to mesenchymal cells
isolated from other organs and undergo transdifferentiation to a
myoﬁbroblast phenotype when plated on tissue culture plastic, we
plated freshly isolated GFP+ cells from uninjured mTmG;Pdgfrb-
Cre skeletal muscle on tissue culture plastic and assessed pro-
ﬁbrotic gene expression. After ﬁve days, these cells strongly
expressed the myoﬁbroblast marker αSMA (Fig. 1i) and after
seven and fourteen days in culture demonstrated upregulation of
myoﬁbroblast associated genes encoding PDGFRβ, αSMA,
Col1a1 and TIMP1 (Fig. 1j). Taken together, these results
demonstrate that Pdgfrb-Cre efﬁciently targets both quiescent
PDGFRβ+ cells and activated myoﬁbroblasts in injured and
ﬁbrotic skeletal muscle.
Cells expressing CD34 and PDGFRα have been shown to label
pro-ﬁbrotic populations in skeletal muscle7, 24, 25. To establish
where PDGFRβ+ cells stand in the hierarchy of previously
recognised cell populations with pro-ﬁbrotic potential during
skeletal muscle ﬁbrosis, we performed immunohistochemistry
and ﬂow cytometry colocalisation studies with anti-CD34 and
anti-PDGFRα antibodies in uninjured and ﬁbrotic skeletal muscle
(Supplementary Fig. 2). We demonstrated 45.8% (SD 3.8)
colocalisation of CD34 with PDGFRβ in uninjured skeletal
muscle and 79.2% (SD 1.2) colocalisation in ﬁbrotic skeletal
muscle. We demonstrated 31.1% (SD 3.6) colocalisation of
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Fig. 1 PDGFRβ-Cre effectively targets recombination in quiescent PDGFRβ+ cells and activated myoﬁbroblasts. a Immunoﬂuorescence micrographs of
skeletal muscle from mTmG;PDGFRβ-Cre mice co-stained with anti-PDGFRβ antibody. Scale bar 10 μm. b, c Quantiﬁcation of GFP reporting and PDGFRβ
antibody colocalisation in skeletal muscle (n= 7). d Flow cytometric analysis of PDGFRβ expression in GFP+ cells sorted from mTmG:PDGFRβ-Cre mouse
skeletal muscle (n= 3). e Immunoﬂuorescence micrographs of skeletal muscle sections harvested from mTmG;PDGFR β-Cre reporter mice 4, 8 and
21 days after control (PBS) or CTX intramuscular injection. Scale bars 30 μm. f Percentage ﬁeld coverage of GFP+ cells at 4, 8, 21 and 60 days after control
(PBS) or CTX intramuscular injection (n= 4). g Quantitation of GFP+ nuclei at 4, 8, 21 and 60 days after control (PBS) or CTX intramuscular injection
(n= 4). h Gene expression proﬁle of freshly sorted GFP+ cells from skeletal muscle at day 10 following control (PBS) or CTX intramuscular injection
(n= 4). i Immunoﬂuorescence staining of a typical GFP+ cell sorted from uninjured skeletal muscle of mTmG;PDGFRβ-Cre reporter mice and plated on
tissue culture plastic for 5 days. Scale bar 50 μm. j qPCR analysis of the genes encoding PDGFRβ, αSMA, Col1A1 and TIMP1 in freshly sorted GFP+ cells
from mTmG;PDGFRβ-Cre reporter mice and from GFP+ cells cultured for 7 and 14 days (n= 4). Data are mean± SEM. *P< 0.05, **P< 0.01, ***P< 0.001,
****P< 0.0001 (Student’s t-test)
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Fig. 2 αv integrins on PDGFRβ+ cells regulate skeletal muscle ﬁbrosis via TGFβ activation. a αv expression on PDGFRβ+ cells from control and Itgavﬂox/ﬂox;
PDGFRβ-Cre (αv Cre) mice using ﬂow cytometry (n= 3). b αv Cre and control mice received intramuscular CTX with muscles harvested at day 21. c
Representative images of picrosirius red stained sections 21 days after CTX. Upper panels: scale bar 25 μm, Lower panels: 400 μm. d Digital image analysis
quantiﬁcation of picrosirius red staining in control and αv Cre mice day 21 post CTX or control injection (n= 7). e qPCR of Col1a1 in control and αv Cre
PDGFRβ+ cells culture-activated for 5 days (n= 7). f qPCR of TGFβ1 in control and αv Cre PDGFRβ+ cells culture-activated for 5 days (n= 7). g qPCR of
Col1a1 in GFP+ cells from mTmG;PDGFRβ-Cre mice cultured with CWHM 12 and control for 5 days (n= 3). h TGFβ activation by control- or CWHM
12-treated GFP+ cells from mTmG;PDGFRβ-Cre mice (n= 6). TGFβ activation was assessed alone, with TGFβ–blocking antibody (Anti–TGFβ), and with
recombinant human TGFβ1 (rhTGFβ). i Representative images of picrosirius red stained sections from mice treated with CWHM12 or control from the time
of CTX. Mice received rhTGFβ1 (lower panels) to the region of injured muscle every 72 h up to 21 days. j Digital image analysis quantitation of picrosirius
red stained sections from CWHM12 or control treated mice that received rhTGFβ1 or PBS to the region of injured muscle (n= 5). k Representative images
of phospho-SMAD 3 stained sections from control or CWHM12-treated mice. Scale bar 30 μm. l Quantitation of phospho-SMAD 3 stained sections from
mice treated with control or CWHM12 from the time of CTX (n= 10). m Force required for passive elongation of muscles 21 days following intramuscular
CTX in mice treated with CWHM 12 or control (n= 9). n Laceration-induced skeletal muscle ﬁbrosis model dosing regime. o Representative images of
picrosirius red stained sections from control and CWHM 12 treated mice. Scale bar 25 μm. p Digital image analysis quantitation of picrosirius red staining in
CWHM12 and control treated mice (n= 10). Data are expressed as mean± SEM. *P< 0.05, **P< 0.01 (Student’s t-test)
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PDGFRα with PDGFRβ in uninjured skeletal muscle and 44.8%
(SD 1.2) colocalisation in injured skeletal muscle. These data
demonstrate that the pro-ﬁbrotic PDGFRβ+ cell population
signiﬁcantly overlaps with the previously described pro-ﬁbrotic
populations in skeletal muscle.
αv integrins on PDGFRβ+ cells regulate skeletal muscle
ﬁbrosis. To establish the utility of Pdgfrb-Cre to identify mole-
cular mechanisms driving skeletal muscle ﬁbrosis, we focussed on
the integrin αv subunit because of the role of αv-containing
integrins in activating latent TGFβ, a central mediator of ﬁbro-
sis17–21, 26, 27. We used ﬂow cytometry to assess αv integrin
expression levels on different cell lineages within uninjured ske-
letal muscle. In addition to the high expression levels observed on
PDGFRβ+ cells, we also found expression of αv integrins on
CD31+, CD34+ and PDGFRα+ populations in skeletal muscle
(Supplementary Fig. 3a–d). Flow cytometry, using an antibody
raised against a portion of the αv extracellular domain, revealed
that αv integrin was efﬁciently depleted from Itgavﬂox/ﬂox;Pdgfrb-
Cre PDGFRβ+ cells in skeletal muscle (Fig. 2a). To induce skeletal
muscle ﬁbrosis, Itgavﬂox/ﬂox;Pdgfrb-Cre and control mice received
intramuscular CTX, with muscles harvested at day 21 for analysis
as previously described28 (Fig. 2b). Itgavﬂox/ﬂox;Pdgfrb-Cre mice
were signiﬁcantly protected from CTX-induced skeletal muscle
ﬁbrosis, as determined by picrosirius red staining for collagen and
digital morphometry (Fig. 2c, d). In keeping with previous stu-
dies29–31, differentiating and regenerating myoﬁbres in skeletal
muscle expressed αSMA, and therefore this marker was not used
in the quantiﬁcation of ﬁbrosis in in vivo sections. To assess
whether itgavﬂox/ﬂox;PDGFRβ-cre mice had an aberrant immune
response to CTX we assessed neutrophil and macrophage inﬁl-
tration in skeletal muscle from CTX treated itgavﬂox/ﬂox;
PDGFRβ-cre and control mice. There was no difference in the
degree of initial injury or inﬂammatory inﬁltrates (Supplementary
Fig. 4a–c), or differences in muscle regeneration following CTX,
as assessed by Evans blue extravasation at day 8 post CTX
injection7 (Supplementary Fig. 4d). Furthermore, depletion of αv
integrins on PDGFRβ+ cells did not affect neovascularisation
following skeletal muscle injury (Supplementary Fig. 4e) between
the two genotypes. These data demonstrate that Pdgfrb-Cre
effectively targets gene deletion to skeletal muscle PDGFRβ+ cells
during ﬁbrogenesis, and that αv integrins in PDGFRβ+ cells
regulate CTX-induced skeletal muscle ﬁbrosis.
Collagen 1 is the major ﬁbrillar collagen deposited in the
extracellular matrix during skeletal muscle ﬁbrosis8. To determine
whether loss of αv integrins affected induction of Col1a1 gene
expression, control and αv-null (αv Cre) skeletal muscle PDGFRβ+
cells were activated in culture for ﬁve days. Col1a1 expression was
signiﬁcantly reduced in α-null PDGFRβ+ cells compared to
control (Fig. 2e). TGFβ1 is a major pro-ﬁbrogenic cytokine and a
potent inducer of collagen gene expression and myoﬁbroblast
transdifferentiation12. Therefore, we assessed TGFβ1 mRNA
levels in control and αv Cre PDGFRβ+ cells, and found similar
levels between the two groups, demonstrating that the reduction
in Col1a1 expression in αv Cre PDGFRβ+ cells is not secondary to
a decrease in TGFβ1 mRNA expression (Fig. 2f).
We then assessed the effect of a small molecule inhibitor of αv
integrins, CWHM 12, and its control enantiomer (CWHM 96) on
Col1a1 gene expression in skeletal muscle PDGFRβ+ cells
activated in culture. CWHM 12 is a synthetic small-molecule
RGD peptidomimetic antagonist that consists of a cyclic
guanidine-substituted phenyl group as the arginine mimetic and
a phenyl-substituted beta amino acid as the aspartic acid mimetic,
both linked by glycine9. CWHM 96 is the R enantiomer of
CWHM 12 and differs only in the orientation of its carboxyl
(CO2H) groups. In previous studies, CWHM 12, but not the
control enantiomer CWHM 96, demonstrated high potency
against αv integrins in in vitro ligand-binding assays9. Treatment
with CWHM 12, but not control (CWHM 96), inhibited Col1a1
expression in skeletal muscle PDGFRβ+ cells in culture (Fig. 2g).
Furthermore, co-culture of control and CWHM 12-treated
PDGFRβ+ cells with mink lung epithelial reporter cells (TMLCs),
expressing ﬁreﬂy luciferase under the control of the TGFβ-
sensitive plasminogen activator inhibitor promoter32, demon-
strated a signiﬁcant decrease in TGFβ activation by CWHM
12-treated cells compared to control (Fig. 2h). This difference was
eliminated by TGFβ blocking antibody or addition of activated
TGFβ1 (Fig. 2h).
Our data presented above suggested that inhibition of αv
integrins on PDGFRβ+ cells represents a valuable therapeutic
strategy in skeletal and cardiac muscle ﬁbrosis. Therefore, we
used the small molecule αv integrin inhibitor CWHM 12 to
determine whether pharmacologic blockade of αv integrins could
attenuate skeletal muscle ﬁbrosis. Mice were treated with the
small molecule inhibitor of αv integrins (CWHM 12) or control
from the time of CTX injury. Treatment with CWHM
12 signiﬁcantly reduced skeletal muscle ﬁbrosis, as determined
by picrosirius red staining for collagen (Fig. 2i). To further
investigate whether the anti-ﬁbrotic effect of αv integrin blockade
is secondary to reduced TGFβ activation in vivo, we administered
recombinant TGFβ1 every 72 h to mice receiving either CWHM
12 or control post CTX injection. Administration of active
recombinant TGFβ1 rescued the anti-ﬁbrotic effect of CWHM 12
(Fig. 2i, j). Furthermore, as we had shown that CWHM 12-treated
PDGFRβ+ cells are defective in their ability to activate TGF-β
in vitro, we extended our ﬁndings in vivo by examining canonical
TGF-β signalling by immunostaining for phosphorylated SMAD3
(p-Smad3) (Fig. 2k, l). Digital image quantiﬁcation demonstrated
signiﬁcantly reduced p-smad3 signalling in skeletal muscles of
mice treated with CWHM 12 compared to control following
intramuscular CTX injection (Fig. 2k, l). Taken together, these
results strongly suggest that the protection from skeletal muscle
ﬁbrosis observed following αv integrin blockade is at least in part
a consequence of reduced TGF-β activation.
In the setting of skeletal muscle ﬁbrosis, stiffness ‘contractures’
result in signiﬁcant morbidity and are a major cause of loss of
muscle function. We therefore used commercially available,
customized muscle physiology testing equipment to assess muscle
stiffness following CTX-induced injury, to provide functional
data with direct clinical relevance. We found that muscle stiffness
was signiﬁcantly reduced in mice treated with CWHM 12
compared to control (Fig. 2m), demonstrating that αv integrin
blockade using CWHM 12 can improve muscle function
following CTX-induced muscle injury.
In order to investigate whether αv integrin-mediated regulation
of skeletal muscle ﬁbrosis is common to different modes of
skeletal muscle injury, we used a laceration model of skeletal
muscle ﬁbrosis33, 34. Pharmacologic blockade of αv integrins
using CWHM 12 delivered via osmotic minipumps protected
mice from laceration-induced ﬁbrosis (Fig. 2n–p), demonstrating
that αv integrin blockade is anti-ﬁbrotic in skeletal muscle models
with very different mechanisms of injury.
To further investigate the mechanisms through which αv
integrin inhibition reduces skeletal muscle ﬁbrosis, we investi-
gated the effects of αv integrin blockade on the migration and
apoptosis of PDGFRβ+ cells isolated from skeletal muscle. We
found that pharmacologic blockade of αv integrins had no effect
on migration or apoptosis of PDGFRβ+ cells isolated from
skeletal muscle (Supplementary Fig. 4f–h).
The αv integrin has ﬁve possible β subunit binding partners
(β1, β3, β5, β6 and β8), each of which has been reported to bind
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and/or activate latent TGFβ. We investigated expression of the
various αv integrin β subunits in PDGFRβ+ reporter cells isolated
from control and ﬁbrotic skeletal muscle (Supplementary Fig. 3e).
We found expression of the genes encoding β1, β3, β5 and β8 on
PDGFRβ+ reporter cells, with signiﬁcant increases in β1, β5 and
β8. As expected, we did not detect expression of the epithelial-
restricted integrin β6.
Selective αv integrins depletion inhibits cardiac ﬁbrosis. Car-
diac myoﬁbroblasts are central mediators of extracellular matrix
deposition during cardiac ﬁbrogenesis and have previously been
shown to express high levels of PDGFRβ11, 27. We therefore
hypothesised that Pdgfrb-Cre marks myoﬁbroblasts in the heart
and allows manipulation of speciﬁc genes in these cells. We
initially examined the hearts of mTmG;Pdgfrb-Cre reporter mice
to conﬁrm the speciﬁcity of Pdgfrb-Cre-induced reporting. As in
skeletal muscle, PDGFRβ staining demonstrated a high degree of
colocalisation with GFP+ reporter cells (Fig. 3a–c). To further
assess speciﬁcity of Pdgfrb-Cre-mediated recombination, we
stained uninjured cardiac muscle from mTmG;Pdgfrb-Cre mice
with antibodies to CD31, ICAM-2 and CD144 (endothelial cells),
CD45 (haematopoietic cells) and fast myosin (myoﬁbres). As
expected, GFP+ reporter cells were consistently found in close
proximity to CD31+ endothelial cells (Fig. 3a, middle panel;
Supplementary Fig. 5a, b). GFP was not expressed by haemato-
poietic cells (Supplementary Fig. 5c) or myoﬁbres (Fig. 3a, lower
panel), further conﬁrming the speciﬁcity of Pdgfrb-Cre to mark
PDGFRβ+ cells in cardiac muscle. To examine the role of
PDGFRβ+ cells in cardiac ﬁbrosis, we administered angiotensin II
(AngII) to mTmG;Pdgfrb-Cre mice for 14 days (Fig. 3d). After
14 days of AngII treatment, GFP+ reporter cells were distributed
between myoﬁbres and throughout the interstitium in a pattern
characteristic for cardiac myoﬁbroblasts (Fig. 3e). Field coverage
of GFP+ reporter cells, and the number of GFP+, DAPI+ nuclei,
were signiﬁcantly increased after 14 days of AngII treatment
(Fig. 3f, g). Expression of the pro-ﬁbrotic gene Col1a1 was sig-
niﬁcantly increased in PDGFRβ+ cells isolated from ﬁbrotic
hearts (Fig. 3h). Furthermore, freshly isolated GFP+ cells from
mTmG;Pdgfrb-Cre mouse hearts activated in culture demon-
strated upregulation of Col1a1 in keeping with transdifferentia-
tion to an activated myoﬁbroblast phenotype (Fig. 3i).
Populations of cells expressing the markers PDGFRα and
CD34 have been implicated in the development of cardiac
ﬁbrosis35, 36. To establish where PDGFRβ+ cells stand in the
hierarchy of previously recognised cell populations with pro-
ﬁbrotic potential in the heart, we performed ﬂow cytometry and
immunohistochemistry colocalisation studies with anti-CD34 and
anti-PDGFRα antibodies in healthy and ﬁbrotic hearts. Using
ﬂow cytometry, we demonstrated 49.1% (SD 2.3) colocalisation of
CD34 with PDGFRβ in uninjured cardiac muscle and 51.5% (SD
8.8) colocalisation in ﬁbrotic cardiac muscle. We demonstrated
44.8% (SD 1.2) colocalisation of PDGFRα with PDGFRβ in
uninjured cardiac muscle and 71.6% (SD 4.7) colocalisation in
ﬁbrotic hearts (Supplementary Fig. 6). These data demonstrate
that the pro-ﬁbrotic PDGFRβ+ cell population signiﬁcantly
overlaps with the previously described pro-ﬁbrotic populations
in the heart.
To investigate whether Pdgfrb-Cre-mediated depletion of αv
integrins on PDGFRβ+ cells protects against cardiac ﬁbrosis, we
treated control or Itgavﬂox/ﬂox;Pdgfrb-Cre mice with vehicle
control or AngII, and harvested hearts after 14 days. Serial blood
pressure measurements conﬁrmed that control and Itgavﬂox/ﬂox;
Pdgfrb-Cre mice displayed an appropriate hypertensive response
to AngII treatment (Fig. 3j). Itgavﬂox/ﬂox;Pdgfrb-Cre mice were
signiﬁcantly protected from AngII-induced cardiac ﬁbrosis, as
determined by collagen staining and digital morphometric
assessment (Fig. 3k, l). The αv integrin has ﬁve possible β
subunit binding partners (β1, β3, β5, β6 and β8), each of which has
been reported to bind and/or activate latent TGFβ. We
investigated expression of the various αv integrin β subunits in
PDGFRβ+ reporter cells isolated from control and ﬁbrotic cardiac
muscle (Supplementary Fig. 7a). We found expression of the
genes encoding β1, β3, β5 and β8 on PDGFRβ+ reporter cells, with
a signiﬁcant decrease in β1 and a signiﬁcant increase in β3 in
PDGFRβ+ reporter cells isolated from ﬁbrotic hearts. As expected,
we did not detect expression of the epithelial-restricted integrin
β6. These data demonstrate that αv integrin depletion on
PDGFRβ+ cells also protects against AngII-induced cardiac
ﬁbrosis.
To investigate whether αv integrin depletion inﬂuences cardiac
hypertrophy we analysed cardiomyocyte cross-sectional area in
hearts from control and Itgavﬂox/ﬂox;Pdgfrb-Cre mice treated for
14 days with AngII. We found no difference in cross-sectional
area of cardiomyocytes between control or Itgavﬂox/ﬂox;Pdgfrb-
Cre mice following AngII treatment (Supplementary Fig. 8a, b).
To further investigate the mechanisms through which αv
integrin inhibition reduces heart ﬁbrosis, we investigated the
effects of αv integrin blockade on the migration and apoptosis of
PDGFRβ+ cells isolated from cardiac muscle. We found that
pharmacologic blockade of αv integrins had no effect on
migration or apoptosis of PDGFRβ+ cells isolated from cardiac
muscle (Supplementary Fig. 9a, b). In addition, depletion of αv
integrins on PDGFRβ+ cells did not affect neovascularisation of
the ﬁbrotic heart (Supplementary Fig. 9c).
We used ﬂow cytometry to assess αv integrin expression levels
on different cell lineages within uninjured cardiac muscle. In
addition to the high expression levels observed on PDGFRβ+
cells, we also found expression of αv integrins on CD31+, CD34+
and PDGFRα+ populations in cardiac muscle (Supplementary
Fig. 7b–e).
αv integrins blockade attenuates skeletal muscle and cardiac
ﬁbrosis. Our data presented above suggested that inhibition of αv
integrins on PDGFRβ+ cells represents a valuable therapeutic
strategy in skeletal and cardiac muscle ﬁbrosis. Therefore, we next
asked whether CWHM 12 can attenuate skeletal muscle and
cardiac ﬁbrosis once established. Mice were injected with CTX
and then 10 days later Alzet pumps containing either CWHM 12
or control (CWHM 96) were inserted for the ﬁnal 11 days of our
protocol (Fig. 4a). Treatment with CWHM 12 signiﬁcantly
reduced skeletal muscle ﬁbrosis compared to control even after
ﬁbrotic disease had been established (Fig. 4b, c).
We then examined whether CWHM 12 could prevent
progression of established cardiac ﬁbrosis. Mice were treated
with AngII via Alzet osmotic minipumps for seven days prior to
insertion of Alzet minipumps containing either CWHM 12 or
control (CWHM 96). Mice then received AngII and either
CWHM 12 or CWHM 96 for a further 7 days (Fig. 4d).
Treatment with CWHM 12 signiﬁcantly reduced cardiac ﬁbrosis
compared to control even after ﬁbrotic disease had been
established (Fig. 4e, f). Therefore, our ﬁndings suggest that
inhibition of αv integrins by the small molecule CWHM 12 has
clinical utility in the treatment of patients with skeletal muscle or
cardiac ﬁbrosis.
In order to determine the plasma and tissue concentrations in
skeletal and cardiac muscle of CWHM 12 and the control
enantiomer CWHM 96, we implanted osmotic minipumps in
C57/BL6 mice and delivered the compounds at a dose of 100 mg
kg−1 day−1. Mice were sacriﬁced at day 3 when the drug had
reached steady state, and terminal plasma, tibialis anterior and
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cardiac muscle samples were taken for compound analysis using
liquid chromatography–mass spectrometry (LC–MS/MS). The
mean CWHM 12 plasma concentration was almost identical to
what we have reported in previous minipump studies using these
compounds37. Furthermore, CWHM 96 plasma levels were
signiﬁcantly higher than CWHM 12 levels, in keeping with
previous studies37. Drug enantiomers frequently exhibit differing
pharmacokinetic parameters because a number of mechanisms
can be stereoselective, among them target interaction, metabolic
clearance, renal clearance and protein binding. For each
compound, the tissue concentrations measured in skeletal and
cardiac muscle were similar to each other (Supplementary
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Fig. 4 Blockade of αv integrins by a small molecule (CWHM 12) attenuates established skeletal muscle and cardiac ﬁbrosis, and αv integrins represent a
tractable therapeutic target in human muscle ﬁbrosis. a Dosing regime in the therapeutic skeletal muscle ﬁbrosis model. Alzet osmotic minipumps
containing CWHM 12 or CWHM 96 (control) were inserted ten days after intramuscular CTX injection. Tissues were harvested at day 21 following CTX
injection. b Representative images of picrosirius red stained sections from control- and CWHM 12-treated mice. Scale bar 25 μm. c Digital image analysis
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14 after commencement of AngII treatment. e Representative images of picrosirius red stained sections from control- and CWHM 12-treated mice. Scale
bars 1 mm in whole heart sections, 70 μm for magniﬁed ﬁelds. f Digital image analysis quantiﬁcation of collagen (picrosirius red staining) (n= 11). g, h Flow
cytometric analysis of PDGFRβ and αv integrin expression on PDGFRβ+ cells from human skeletal muscle (g) and heart (h). i, j TGFβ activation by control-
or CWHM 12-treated PDGRβ+ cells isolated from human skeletal muscle (i) and cardiac muscle (j) (n= 4). TGFβ activation was assessed alone, in the
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are expressed as mean± SEM. *P< 0.05, **P< 0.01 (Student’s t-test)
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Fig. 10). These data demonstrate that the small molecule αv
integrin inhibitor (CWHM 12) was present in plasma, skeletal
muscle and cardiac muscle at the expected concentrations.
αv integrins on PDGFRβ+ cells are a potential therapeutic
target. To further explore whether αv integrins represent a
tractable therapeutic target in human skeletal muscle and cardiac
ﬁbrosis, we sorted PDGFRβ+ cells from human skeletal and
cardiac muscle. Flow cytometric analysis of PDGFRβ+ cells iso-
lated from human skeletal muscle demonstrated that the vast
majority of these cells also expressed αv integrins (Fig. 4g). Co-
culture of CWHM 12- or control- (CWHM 96) treated human
skeletal muscle PDGFRβ+ cells with TMLCs demonstrated a
signiﬁcant reduction in TGFβ activation by PDGFRβ+ cells
treated with CWHM 12 compared to control (Fig. 4i). This dif-
ference was eliminated by addition of TGFβ-blocking antibody or
by addition of activated TGFβ1 (Fig. 4i). Furthermore, ﬂow
cytometric analysis of PDGFRβ+ cells isolated from human heart
demonstrated that the vast majority of these cells also expressed
αv integrins (Fig. 4h). Co-culture of CWHM 12- and control-
(CWHM 96) treated human cardiac PDGFRβ+ cells with TMLCs
demonstrated a signiﬁcant reduction in TGFβ activation by
PDGFRβ+ cells treated with CWHM 12 compared to control
(Fig. 4j). This difference was eliminated by addition of TGFβ-
blocking antibody or addition of activated TGFβ1 (Fig. 4j). Taken
together, these data demonstrate that αv integrins are highly
expressed and targetable on PDGFRβ+ cells in both human ske-
letal and cardiac muscle, and therefore represent a potential novel
therapeutic target in the treatment of skeletal muscle and cardiac
ﬁbrosis.
Discussion
Muscle ﬁbroses, including skeletal and cardiac muscle ﬁbrosis, are
major causes of morbidity and mortality worldwide, however
treatment options for these conditions remain severely
limited6, 38. Therefore, in order to aid the design of rational,
targeted, anti-ﬁbrotic therapies to treat patients with skeletal
muscle or cardiac ﬁbrosis, we used Pdgfrb-Cre to help identify the
key molecular mechanisms driving muscle ﬁbrosis. We found
that Pdgfrb-Cre effectively targeted quiescent PDGFRβ+ cells and
activated myoﬁbroblasts in both skeletal and cardiac muscle.
Selective depletion of αv integrins on PDGFRβ+ cells protected
mice from ﬁbrosis in both these muscle types, and αv integrin
depletion on PDGFRβ+ cells had no adverse effects on skeletal
muscle regeneration, underlining the potential therapeutic utility
of this approach to treat muscle ﬁbrosis. Furthermore, treatment
with a small-molecule inhibitor of αv integrins (CWHM 12)
attenuated ﬁbrosis in both skeletal muscle and heart, even after
the ﬁbrotic process had become established, suggesting that
inhibition of this pathway may be effective in a clinical setting,
where patients typically present with pre-existing muscle ﬁbrosis.
In addition, we demonstrated that skeletal muscle stiffness was
signiﬁcantly reduced in mice treated with CWHM 12 compared
to control, demonstrating that αv integrin blockade using
CWHM 12 can improve muscle function following CTX-induced
muscle injury.
We found that treatment with CWHM 12 inhibited Col1a1
expression in skeletal muscle PDGFRβ+ cells in culture. Fur-
thermore, CWHM 12 treatment, in both primary mouse and
human PDGFRβ+ cells isolated from skeletal and cardiac muscle,
demonstrated a signiﬁcant decrease in TGFβ activation compared
to control, suggesting that αv integrins on PDGFRβ+ cells regulate
skeletal and cardiac muscle ﬁbrosis, at least in part, via the acti-
vation of TGFβ. Targeted blockade of TGFβ1 signalling during
muscle ﬁbrogenesis, through inhibition of αv integrins with a
small molecule such as CWHM 12, may yield the desired anti-
ﬁbrotic effects without the unwanted, potentially deleterious side
effects of pan-TGFβ blockade, such as induction of autoimmunity
or carcinogenesis15.
Myoﬁbroblasts are the major source of extracellular matrix
proteins during muscle ﬁbrogenesis4, and a number of putative
myoﬁbroblast progenitor populations have been implicated in the
development of muscle ﬁbrosis, including ﬁbro-adipogenic
progenitors7, 8, 24, and cells expressing Gli111, ADAM1228 and
PDGFRα8. However, despite PDGFRβ+ mesenchymal cells being
extensively studied in the context of solid organ ﬁbrosis, much
less is known about the role of these mesenchymal cells in the
regulation of muscle ﬁbrogenesis. We saw signiﬁcant expansion
of PDGFRβ+ cells in both cardiotoxin-induced skeletal muscle
ﬁbrosis and AngII-induced model of cardiac ﬁbrosis, suggesting
that proliferation of PDGFRβ+ cells is a conserved injury response
in different types of muscle, regardless of the initial mode of
muscle injury. In keeping with widespread use of PDGFRβ as a
pericyte marker39, 40, Pdgfrb-Cre used in the present study
labelled perivascular cells in uninjured skeletal and cardiac
muscle. However, the co-labelling of PDGFRβ with PDGFRα+
and CD34+ populations indicates that the pro-ﬁbrotic PDGFRβ+
cell population in skeletal and cardiac muscle signiﬁcantly over-
laps with the previously described pro-ﬁbrotic cells including
ﬁbro-adipogenic progenitors and cardiac ﬁbroblasts7, 8, 35, 36.
Of note a recent paper by Guimarães-Camboa et al.41 sug-
gested that Pdgfrb-Cre extensively labels multiple cellular lineages
including endothelial and haematopoietic lineages in cardiac and
skeletal muscle. To investigate the discrepancy between our data
using Pdgfrb-Cre in skeletal and cardiac muscle and the data
published by Guimarães-Camboa et al., we stained skeletal and
cardiac muscle from mTmG;Pdgfrb-Cre reporter mice with the
hematopoietic marker CD45 and found no colocalisation between
PDGFRβ reporter cells and CD45 (Supplementary Figs. 1 and 5).
We also stained skeletal and cardiac muscle from mTmG;Pdgfrb-
Cre reporter mice with the endothelial markers CD31, CD144
and ICAM-2 and demonstrated no colocalisation of PDGFRβ
reporter cells with CD31, CD144 and ICAM-2 (Supplementary
Fig. 1 and 5). Furthermore, data published by Guimarães-
Camboa et al.41 suggested that recombination of myoﬁbres was
widespread in skeletal muscle in Pdgfrb-Cre reporter mice.
However, in marked contrast we have not seen widespread
recombination of myoﬁbres in Pdgfrb-Cre reporter mice, as evi-
denced by 97.5% (SEM 0.46) of cells staining for PDGFRβ
reporting GFP, and 95.3% (SEM 1.08) of GFP+ cells staining
positively for PDGFRβ (Fig. 1b, c). Virtually all GFP+ cells sorted
from mTmG;Pdgfrb-Cre mouse skeletal muscle stained positively
with anti-PDGFRβ antibody on ﬂow cytometric analysis (Fig. 1d).
Furthermore, we demonstrate a lack of colocalisation of PDGFRβ
reporter cells with anti-myosin staining in skeletal muscle of
Pdgfrb-Cre reporter mice (Supplementary Fig. 1), and as evi-
denced by multiple images throughout our article we do not see
widespread recombination of myoﬁbres in skeletal muscle of
PDGFRβ Cre reporter mice.
Functional heterogeneity within skeletal and heart muscle
mesenchymal cells is increasingly being recognised. It is highly
likely that in the coming years distinct mesenchymal sub-
populations and subclasses will be identiﬁed and characterised
that are the major regulators of muscle injury, ﬁbrosis and
regeneration. Ever-increasing ﬁdelity in the elucidation of the key
functional subpopulations of muscle mesenchymal cells will
hopefully facilitate the discovery of highly targeted, potent, anti-
ﬁbrotic treatments. Ideally this will allow therapeutic inhibition of
the pro-ﬁbrogenic subpopulations, whilst not perturbing the
function of the mesenchymal populations involved in normal
tissue homeostasis and regeneration.
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Methods
Mice. mTmG (TdTomato-GFP)23 were obtained from the Jackson Laboratory and
crossed with Pdgfrb-Cre mice42 provided by R. Adams. Itgavﬂox/ﬂox mice43 were
obtained from A. Lacy-Hulbert, and were maintained on C57BL/6 background.
Genotyping of mice was performed by PCR. Wild type C57BL/6 mice were pur-
chased from Charles River. Mice used for experiments were males aged 8–12 weeks
and were housed under speciﬁc pathogen-free conditions. All animal work was
approved by the UK Home Ofﬁce, or by the Institutional Animal Care and Use
Committee of the University of Texas. Sample sizes were based on extensive
previous experience with muscle ﬁbrosis models. Animals were randomly allocated
to experimental groups. Investigators collecting data were blinded to treatment
groups.
Fibrosis models. CTX muscle injury was induced as described previously28. Mice
were injected with 50 μl of 20 μM cardiotoxin (Sigma) or PBS (control) into the
tibialis anterior muscle. Mice were culled and muscles harvested at 4, 8, 21 and
60 days following CTX injection. To assess muscle damage and the regenerative
response following CTX injection, mice were injected intraperitoneally with Evans
blue dye (25 mg kg−1) 24 h prior to sacriﬁce at 8 days post CTX injection as
previously described7.
The skeletal muscle laceration model was performed as previously described33, 34.
The mice were anesthetized using pentobarbital sodium (80mg kg−1) (Anpro
Pharmaceuticals, Arcadia, CA, USA) delivered by intraperitoneal injection. The
muscles were lacerated with a surgical blade (no. 11) at the largest diameter,
through the lateral 50% of their width and 100% of their thickness. Polydioxanone
suture material (PDSII 5-0, Ethicon, Somerville, NJ, USA), 4 mm in length, was
placed at the medial edge of the lacerated side of each leg as a marker for the
lacerated site. After the laceration was made, the skin was closed with 4-0 silk. All
animals were sacriﬁced for evaluation of ﬁbrosis at 21 days.
Myocardial ﬁbrosis was induced as described previously44. Angiotensin II
(Sigma) dissolved in sterile water was administered at 200 ng kg−1 min−1 for
14 days via subcutaneous Alzet osmotic minipumps (Durect Corporation). Prior to
pump implantation, mice were conditioned to tail cuff blood pressure
measurement for several days. Blood pressure was assessed on the day of surgery
(day 0) and pumps were implanted under general anaesthesia (isoﬂurane in 100%
oxygen). Further blood pressure measurements were taken on days 3, 7, 10 and
ﬁnally on day 14 prior to sacriﬁce.
Primary cell isolation and cell sorting. Mouse skeletal muscle was excised,
minced and digested in collagenase/dispase solution (DMEM/20%FBS/1%PS/0.5
mg ml−1 of collagenase II-S and dispase (Sigma-Aldrich)) for 30 min at 37 °C with
shaking (200–250 r.p.m.). An equal volume of DMEM/20%FBS/1%PS was added to
halt the digestion and the total suspension was passed through a sterilized nylon
mesh to remove large clumps. The suspension was then passed through a 100 µm
followed by a 70 µm strainer and centrifuged (300 × g, 5 min). The supernatant was
discarded and the pellet re-suspended in 10 ml red cell lysis buffer (Sigma) and
incubated at room temperature for 1 min. An equal volume of DMEM/20%FBS/1%
PS was added and the suspension centrifuged (300 × g, 5 min). The supernatant
was discarded and the pellet re-suspended in 1 ml FACS buffer (PBS/2%FBS) and
passed through a 40 µm strainer. Cells were counted using a haemocytometer using
trypan blue to distinguish non-viable cells. A similar procedure was followed in the
preparation of cardiac muscle. The atria and major vessels were removed and the
remaining tissue was minced and digested using 200 Uml−1 of Collagenase II
(Gibco). Three serial digestions of 10 min were performed, each followed by
removal and quenching of enzyme activity with DMEM/20%FBS/1%PS. Treatment
of the suspension was as described for skeletal muscle.
Isolation of GFP+ cells from mTmG; Pdgfrb-Cre reporter mice: Following live/
dead staining with DAPI (Invitrogen), live single GFP+ cells from mTmG;Pdgfrb-
Cre mice were sorted using a FACSAria Cell Sorter (BD Biosciences). Fluorescence
compensation settings were optimised using anti-mouse Ig, κ/negative control
beads plus (BD Biosciences) incubated with GFP antibody (BD Bioscience).
Unstained cells from mTmG;Pdgfrb-Cre negative mice were used to account for the
autoﬂuorescence of samples and an isotype (BD Bioscience) was used as a negative
control. The gating strategy used to isolate GFP+ cells is shown in Supplementary
Fig. 11a.
Isolation of PDGFRβ+ cells from non-reporter tissue: When sorting non-
reporter tissues, an anti-PDGFRβ antibody was used to identify PDGFRβ+ cells. In
brief, cells were re-suspended at a concentration of 3.0 × 107 ml−1 and incubated
with anti-PDGFRβ antibody (phycoerythin- (PE) conjugated, clone ABP5, 1:50, no.
136006, Biolegend). As controls, 5 × 105 cells were incubated with the isotype
control (PE Rat IG2bα, clone RTK27581:50, no. 400508, Biolegend) in the same
conditions. Cell suspensions were washed with FACS buffer and centrifuged (300 ×
g, 5 min). The supernatant was then discarded and the cells re-suspended in 1 ml
FACS buffer prior to sorting. Fluorescence compensation settings were optimised
using anti-mouse Ig, κ/negative control beads plus (no. 560497, BD Biosciences)
incubated with the anti-PDGFRβ antibody. Unstained cells were used to account
for the autoﬂuorescence of samples and ﬂuorescently-matched isotypes were used
as negative controls. Prior to selection of PDGFRβ+ cells, a side versus forward
scatter plot was used to remove debris, then a height versus width plot was used to
eliminate doublets. DAPI (0.1–0.5 µg ml−1 (Invitrogen)) was used to stain dead
cells (Supplementary Fig. 11b).
Primary cell culture. Sorted cells were seeded onto tissue culture plates, at a
density of 2 × 104 cells per cm2 and cultured in high-glucose DMEM/20%FBS/1%
PS in a 37 °C, 5% CO2 incubator. Medium was refreshed three times per week, with
cells passaged on reaching 90% conﬂuence.
Flow cytometry. Cells were washed twice with PBS and re-suspended in FACS
buffer. 4 × 105 cells were then incubated with a conjugated antibody (or isotype
control) at 4 °C for 30 min in the dark. Cells were then washed, re-suspended in
FACS buffer and analysed on a Becton Dickinson LSR Fortessa II. Antibodies used
were Rat anti mouse PE-conjugated antibody to PDGFRβ (Clone APB5,1:50, no.
136006, Biolegend) and isotype control (PE Rat IG2bα 1:50, Clone RTK2758 no.
400508, BD Bioscience); Rat anti mouse PE-conjugated antibody to αv (CD51)
(Clone RMV-7, 1:200, no. 12-0512-83 eBioscience) and isotype control (PE Rat
IgG1κ 1:200, no. 12-4301-83, eBioscience); Rat anti mouse AF700-conjugated
antibody to CD34 (Clone RAM34, 1:100, no. 560518, BD Bioscience) and isotype
control (AF700 Rat IgG2b, Clone A95-1, 1:100, no. 557964, BD Bioscience); Rat
anti mouse APC-conjugated antibody to CD31 (Clone 390, 1:100, no. 102410
BioLegend) and isotype control (APC Rat IgG2a, Clone RTK2758, 1:100, no
400511, BioLegend); Rat anti mouse APC-conjugated antibody to PDGFRα (Clone
APA5, 1:100, no. 562777, BD Bioscience) and isotype control (APC Rat IgG2a,
Clone R35-95, 1:100, no. 553932, BD Bioscience).
In vivo CWHM 12 and CWHM 96 studies. For all studies CWHM 12 and
CWHM 96 were solubilized in 50% DMSO (in sterile water) and dosed to 100 mg
kg−1 day−1. Drug or vehicle (50% DMSO) were delivered by implantable Alzet
osmotic minipumps (Durect). For CTX-induced ﬁbrosis, pumps were inserted
subcutaneously either before the CTX injection or ten days following the CTX
injection. For laceration-induced ﬁbrosis, pumps were inserted subcutaneously
before the laceration was performed. Muscles were harvested after 21 days. For
AngII-induced cardiac ﬁbrosis, pumps were inserted subcutaneously seven days
after AngII dosing commenced. Hearts were harvested 14 days after AngII dosing
commenced.
In vivo TGFβ1 rescue experiment. Mice were treated with the small molecule
inhibitor of αv integrins (CWHM12) and control from the time of CTX induced
skeletal muscle injury. Mice then received recombinant TGFβ1 (50ng, recombinant
human TGFβ1; R&D Systems, Minneapolis, MN, USA) injections every 72 h to the
region of CTX-induced muscle injury in a volume of 50 μl of PBS. Muscles were
collected for analysis at 21 days.
Apoptosis assay. Cells were seeded in 6 well plates and treated with 0.1 μM
CWHM 12 or CWHM 96 or 1μM staurosporine for 6 h. Cells were lysed and
assayed for cleaved caspase 3 by ELISA (Human/mouse cleaved caspase-3 (ASP-
175) Cat. No. DYC835-2 R&D systems).
Migration assay. 1 × 105 cells in serum free media were seeded in the top of a
8 µm pore size, 5.7 mm diameter, PCTE ChemoTx disposable membrane (Neu-
roprobe) and media containing 10% FCS with or without 0.1 μM CWHM 12 or
CWHM 96 was added to the lower chamber. Cells were allowed to migrate for 3 h
and 18 h at 37 °C. Cells were wiped from the upper surface of the membrane and
cells on the underside were ﬁxed in 70% ethanol and stained with Diffquick
(Fischer Scientiﬁc). Migrated cells were quantiﬁed colorimetrically at 550 nm and
expressed as % of total (unwiped) cells.
Determination of CWHM 12 and CWHM 96 in plasma and tissue. Plasma
samples (50 µl total volume) were diluted with control naive mouse plasma as
appropriate to bring sample into the range of the standard curve. Tissue samples
(skeletal and cardiac muscle) were homogenized at 0.2 g tissue/1 ml PBS using a
mini-beadbeater (Biospec Products, Bartlesville, OK, USA). Tissue homogenates
were extracted neat (0.2 g ml−1) (50 µl total volume). Corresponding naïve control
mouse matrices were used to construct individual plasma and tissue standard
curves. Internal standard was added to all samples and standards at 200 ng ml−1
(ﬁnal), followed by a protein precipitation extraction with 150 µl of acetonitrile.
The samples were capped and mixed on a multiplate vortexer for 5 min and
centrifuged for 5 min at 3200 r.p.m. The supernatant was transferred to a 96-well
sample plate and capped for LC–MS/MS analysis using a system consisting of an
LC-20AD pump (Shimadzu, Kyoto, Japan), an HTC PAL autosampler (Leap
technologies, Carrboro, NC, USA), and a Sciex API-4000 mass spectrometer in ESI
mode (AB Sciex, Foster City, CA, USA). An Amour C18 reverse-phase column
(2.1 × 30 mm, 5 µm; Analytical Sales and Services, Pompton Plains, NJ, USA) was
used for chromatographic separation. Mobile phases were 0.1% formic acid
(aqueous) and 100% acetonitrile (organic) with a ﬂow rate of 0.35 ml min−1.
The starting phase was 10% acetonitrile for the 0.9 min, increased to 90%
acetonitrile over 0.4 min, maintained for an additional 0.2 min, returned to 10%
acetonitrile over 0.4 min, and then held for 1.6 min. The multiple reaction
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monitoring (MRM) transition for CWHM 12 was as follows: mass-to-charge (m/z),
590.13> 234.1. Peak areas were integrated using Analyst 1.5.1 (AB Sciex, Foster
City, CA, USA).
Immunohistochemistry and immunoﬂuorescence. For immunoﬂuorescence
staining, skeletal muscle tissue was ﬁxed in 4% paraformaldehyde overnight at 4 °C,
immersed in graded sucrose solutions, embedded in OCT (Tissue Tek), and ﬂash
frozen in liquid nitrogen before storage at −80 °C. The following primary anti-
bodies were used for immunohistochemistry: PDGFRβ (Rabbit anti human/mouse
clone Y92, 1:50, no. ab32570, Abcam), Myosin (Mouse anti human/mouse, Clone
NOQ7.5.4D, 1:1000, no. M4276, Sigma), GR1 (Rat anti mouse, 1:750, MAB1037,
R&D), F4/80 (Rat anti mouse, Clone Cl:A3-1, 1:100, no. ab6640, Abcam), Isolectin
B4 (1:100, no. I21411, Life Technologies), PDGFRα (Rabbit anti mouse/human,
Clone D1E1E, 1:50, no. 31745S, Cell Signalling), CD34 (Rabbit anti mouse/human,
Clone EP373Y, 1:100, no. ab81289, abcam), ICAM-2 (Rat anti mouse, Clone 3C4
(mlC2/4), 1:50, no. 553326, BD Pharminogen), CD45 (Rat anti mouse, 1:50, no.
MAB114R, R&D), CD144 (Rat anti mouse, Clone 11D4.1, 1:50, no. 555289, BD
Pharminogen) and CD31 (Rat anti mouse, Clone MEC 13.3, 1:50, no. 550274, BD
Pharminogen). Sections were washed with Dulbecco’s PBS (DPBS)/Tween20 pH7.4
(2 × 5 min) then blocked for one hour with 5% goat serum. After blocking, sections
were incubated with ﬂuorochrome-conjugated antibodies overnight at 4 °C or were
blocked to prevent non-speciﬁc avidin and biotin interactions prior to overnight
incubation with the primary antibody at 4 °C. Sections incubated with primary
antibodies were washed with DPBS/Tween20 pH 7.4 (2 × 5 min) prior to incuba-
tion with the secondary antibody for one hour at RT. All sections were then washed
with DPBS/Tween20 pH 7.4 (2 × 5 min) and incubated with DAPI (5 µg ml−1) and
Alexa Fluor-coupled streptavidin [1:1000 (Invitrogen)] for 45 min. After a ﬁnal
DPBS/Tween20 pH 7.4 wash (2 × 5 min), the sections were mounted in ﬂuorescent
mounting medium (Dako) and allowed to dry for 1 hour. Confocal imaging was
performed on a Leica SP8 microscope.
Percentage ﬁeld coverage of GFP+ cells was calculated by capturing 10 random
confocal images from cryosections of mouse skeletal muscle at 4, 8, 21 and 60 days
after control (PBS) or CTX intramuscular injection. GFP reporting was subjected to
threshold processing and calculation of percentage ﬁeld coverage using ImageJ
software45. Antibody staining for CD31, GR1 and F4/80 was quantiﬁed by
capturing ten random ﬂuorescent images from cryosections of mouse skeletal
muscle. Antibody staining was subjected to threshold processing and calculation of
percentage ﬁeld coverage using ImageJ software. All images within an experiment
were processed equally.
For assessment of cardiomyocyte cross-sectional area heart sections were
stained with rhodamine labelled antibody to wheat-germ agglutinin (Vector
Laboratories RL-1022) to label cell membranes and DAPI to label nuclei. Ten ×200
magniﬁcation random ﬁelds were captured per heart using a ﬂuorescence
microscope and the cross-sectional area of cells with central nuclei was calculated.
Parafﬁn-embedded mouse sections were stained for picrosirius red and
haematoxylin and eosin. Blinded, stained sections (5 μm) were quantiﬁed using
ImageJ software. For skeletal muscle, ten random ﬁelds from each section,
generated using a stereologer microscope, were analysed at a ﬁnal magniﬁcation of
×40. For quantiﬁcation of heart ﬁbrosis, unﬁxed hearts were bisected transversely
at the midlevel of the left ventricle and the basal portion was ﬁxed in 10% neutral
buffered formalin. Six transverse sections, separated by approximately 50 µm, were
taken from the cut surface and stained with picrosirius red and, from these, three
sections, in which the papillary muscle insertions were clearly visible, were selected
for assessment. Threshold analysis was carried out on each section to quantify the
area occupied by collagen deposits as a percentage of the total area of the left and
right ventricles and inter-ventricular septum. A mean value was generated based on
the results from the three sections.
For assessment of phospho-SMAD 3 staining parafﬁn-embedded sections were
de-parraﬁnized in xylene (2 × 5 min) and rehydrated through 100–50% alcohols (2
min each) before being pre-treated with 3% hydrogen peroxide for 10 min at room
temperature (RT). Slides were then washed with PBS (2 × 3 min) followed by
antigen retrieval with Tris-EDTA (pH 9) 20 min. Slides were then washed with PBS
(2 × 3 min) and mounted in Sequenza racks before being incubated with Avidin
and Biotin block (Vector, SP-2100) for 15 min each with PBS washes in between
(2 × 3 min). Slides were then incubated with 20% goat serum for 30 min at RT,
followed by overnight incubation with anti-phospho-SMAD3 antibody (1:100,
Abcam Ab52903) at 4 °C before washing with PBS (2 × 3 min). Sections were then
washed with PBS (2 × 3 min) then incubated with goat anti-rabbit biotinylated
antibody (1:1000, Vector, BA-1000) for 30 min at RT followed by PBS wash
(2 × 3 min). Slides were then incubated with Vectastain Elite ABC reagent (Vector,
PK-7100) for 30 min and washed with PBS (2 × 3 min) before incubation in DAB
substrate kit (Dako, K3468) for 10 min at RT followed by PBS wash (2 × 3 min).
Slides were then counter-stained with Harris haematoxylin and Scotts tap water.
For each blinded, stained section twelve random ﬁelds were generated using a
stereologer microscope, and the number of DAB-positive nuclei were counted at a
ﬁnal magniﬁcation of ×40.
For quantiﬁcation of heart ﬁbrosis, unﬁxed hearts were bisected transversely at
the midlevel of the left ventricle and the basal portion was ﬁxed in 10% neutral
buffered formalin. Six transverse sections, separated by approximately 50 µm, were
taken from the cut surface and stained with picrosirius red and, from these, three
sections, in which the papillary muscle insertions were clearly visible, were selected
for assessment. Threshold analysis was carried out on each section to quantify the
area occupied by collagen deposits as a percentage of the total area of the left and
right ventricles and inter-ventricular septum. A mean value was generated based on
the results from the three sections.
Assessment of recombination efﬁciency. Ten confocal images (63×) were ran-
domly acquired throughout non-adjacent cryosections of skeletal and cardiac
muscle. Antibody staining for PDGFRβ and expression of GFP in skeletal muscle
from mTmG:Pdgfrb-Cre mice were separately subjected to threshold processing
using ImageJ software and then the percentage of GFP+ cells staining PDGFRβ+,
and the percentage of PDGFRβ+ cells expressing GFP were quantiﬁed.
TGFβ activation assay. PDGFRβ+ cells isolated by FACS were cultured in
DMEM/20%FBS/1%PS for 5 days on tissue culture plastic and then plated at
5 × 104 cells per well in 96-well plates with 1.5 × 104 mink lung epithelial cells
(TMLCs), expressing ﬁreﬂy luciferase downstream of a TGFβ sensitive portion of
the plasminogen activator inhibitor-1 promoter. Cells were cultured for 16 h in
DMEM/20%FBS/1%PS in the presence of CWHM 12 or CWHM 96 (control), with
or without the addition of recombinant human TGFβ1 (R&D) or TGFβ-blocking
antibody. TGFβ activity was calculated by measurement of luminescence following
cell lysis and addition of ATP/luciferin. Luminescence data was normalised by
measurement of total protein levels. Recombinant human TGFβ1 was reconstituted
as per the manufacturer’s instructions.
Human skeletal and cardiac muscle tissue. The use of human tissues for
this study was approved by the Local Ethics Committee at the University of
Edinburgh.
qRT-PCR. Total RNA was isolated using an RNeasy Micro Kit (Qiagen). cDNA
was analysed by SYBR-Green real-time PCR with a Roche Lightcycler and nor-
malized to β-actin. Primers used were as follows: Actb forward: TGTTACC
AACTGGGACGACA, Actb reverse: GGGGTGTTGAAGGTCTCAAA; Itgav for-
ward: CCGTGGACTTCTTCGAGCC, Itgav reverse: CTGTTGAATCAAACT-
CAATGGGC; Pdgfrb forward: TCCAGGAGTGATACCAGCTTT, Pdgfrb reverse:
CAGGAGCCATAACACGGACA; Acta2 forward: GTCCCAGACATCAGGGA
GTAA, Acta2 reverse: TCGGATACTTCAGCGTCAGGA; Col1a1 forward:
GCTCCTCTTAGGGGCCACT, Col1a1 reverse: CCACGTCTCACCATTGGGG;
Col 3a1 forward: AACCTGGTTTCTTCTCACCCTTC, Col 3a1 reverse: ACTC
ATAGGACTGACCAAGGTGG; Tgfb1 forward: CTCCCGTGGCTTCTAGTGC,
Tgfb1 reverse: GCCTTAGTTTGGACAGGATCTG; Mmp2 forward: CAAGTTCC
CCGGCGATGTC, Mmp2 reverse: TTCTGGTCAAGGTCACCTGTC; Mmp13
forward: CTTCTTCTTGTTGAGCTGGACTC, Mmp13 reverse: CTGTGGAGGT
CACTGTAGACT; Timp1 forward: TGCAACTCGGACCTGGTCATA, Timp1
reverse: CGCTGGTATAAGGTGGTCTCG. Itgb1 forward: CTACTTCTGCACG
ATGTGATGAT, Itgb1 reverse: TTGGCTGGCAACCCTTCTTT; Itgb3 forward:
CCACACGAGGCGTGAACTC, Itgb3 reverse: CTTCAGGTTACATCGGGGTGA;
Itgb5 forward: GAAGTGCCACCTCGTGTGAA, Itgb5 reverse: GGACCGTGGAT
TGCCAAAGT; Itgb8 forward: CTGAAGAAATACCCCGTGGA, Itgb8 reverse:
ATGGGGAGGCATACAGTCT.
Skeletal muscle functional testing. Mechanical assessment of the muscle tissue
was performed in situ using custom mechanical testing apparatus, Aurora Scientiﬁc
1300A (Aurora Scientiﬁc, Ontario, Canada) ﬁtted with a 1 N load cell. The control
and data acquisition was achieved in LabVIEW v8.5 (National Instruments, TX,
USA) using Aurora Scientiﬁc control and analysis programs DMCv5.500 and
DMAv5.300 respectively. Anaesthesia was achieved using 4% isoﬂurane in 100%
oxygen in an induction chamber and was maintained using 2% isoﬂurane in
oxygen via nosecone during dissection and mechanical assessment. The tibialis
anterior muscle was dissected and a 5-0 silk suture (Ethicon) was secured around
the tendon distally. The mouse was securely held in place on a testing mat and kept
warm during the mechanical evaluation by a heating lamp. Saline solution was
applied via pipette to the exposed muscle to prevent dehydration during the
experimental process. The leg was secured in place using a custom U-clamp
attached at the proximal tibial plateau and a BD PrecisionGlide 25 G needle (BD,
NJ, USA) behind the patella tendon. The silk suture was attached to the lever arm
of the mechanical testing apparatus by a BD PrecisionGlide 27 G needle (BD, NJ,
USA). A pre-load of 1 g was applied to the muscle by adjusting the position of the
testing lever via the micromanipulator. Muscle stiffness was assessed by applying a
displacement of 1 mm at a rate of 2 mm s−1. The force and displacement data was
recorded to PC via an Aurora Scientiﬁc 604 A signal interface (Aurora Scientiﬁc,
Ontario, Canada). Mechanical evaluation was performed blinded to the treatment
received.
Statistical analyses. All data are presented as mean± SEM. Statistical signiﬁcance
was calculated using unpaired Student’s t-tests. Differences with a P-value < 0.05
were considered statistically signiﬁcant.
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Data availability. The data sets generated during and/or analysed during the
current study are available from the corresponding authors on reasonable request.
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